ESMO 2023 | The role of erdafitinib in treating patients with bladder cancer

Robert A. Huddart, PhD, FRCR, MRCP, MBBS, The Institute of Cancer Research, London, UK, discusses the results of recent trials involving erdafitinib, a fibroblast growth factor receptor (FGFR) kinase inhibitor as a treatment for various subtypes of bladder cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.